“End products however must provide outstanding usability as well as value to the patient, clinician and payer meaning we have been forced to make some tough investment decisions.” Proteus Health , whose " chip - in - a - chip " collaboration with Otsuka was approved by the US FDA earlier this month , has urged the UK NHS to follow suit and " think about the way they should be " , adding " it 's not sustainable to keep going the way we are " . The company 's sensor pills allow patients to check the pill is being correctly metabolised , and check they are keeping to their regimen , the latter issue afflicting up to 90 % of prescription medication in the UK .
Proteus Health , whose " chip - in - a - chip " collaboration with Otsuka was approved by the US FDA earlier this month , has urged the UK NHS to follow suit and " think about the way they should be " , adding " it 's not sustainable to keep going the way we are " . The company 's sensor pills allow patients to check the pill is being correctly metabolised , and check they are keeping to their regimen , the latter issue afflicting up to 90 % of prescription medication in the UK .